Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY2927088 coated · 1 trial · 4 indications
Based on radioactivity excreted in urine and feces, and vomit as a percentage of the dose to assess mass balance of total radioactivity
| Arm | Type | Description |
|---|---|---|
| Healthy male participants from Netherlands | EXPERIMENTAL | In Part 1, participants will receive a single dose of 40 mg of BAY2927088 as oral tablets on Study Day 1 approximately 30 min after a light meal, they will then receive a single dose of a microtracer not exceeding 100 ug of \[14C\]-BAY2927088 and 37 kilo becquerel (kBq) \[1000 nano Curie (nCi)\] of 14C will be administered intravenously (IV) as a 15 min infusion ending at the expected median time to maximum concentration (tmax) for the tablet (2 hours oral post-dose). After 2 days of washout, participants will move on to Part 2. In Part 2, on Study Day 1 approximately 30 min after a light meal, all enrolled participants will receive a single dose of 40 mg BAY2927088 containing approximately 3.7 MBq (100 µCi) \[14C\]-BAY 2927088 administered as an oral solution |
| Name | Type | Description |
|---|---|---|
| BAY2927088 coated tablet 10 mg | DRUG | 4 coated tablets (10 mg) per single dose 30 min after a light meal |
| [14C]-BAY2927088 solution for infusion | DRUG | IV infusion 15 min ending at 2 hours oral post-dose |
| [14C]-BAY2927088 oral solution | DRUG | After a light meal |
Inclusion Criteria: * Capable of giving signed informed consent * Participant must be 18 or age of legal maturity to 55 years of age inclusive, at the time of signing the informed consent * Participants who are overtly healthy as determined by the investigator or medically qualified designee based ...
Top 20 of 84 competitors
BAY2927088 is an investigational small molecule being developed for advanced non-small cell lung cancer. It is currently in Phase 1 clinical development. The drug is being studied in healthy male participants to understand how it is taken up and handled by the body.
BAY2927088 is being developed by Bayer AG, a pharmaceutical company. Bayer's stock is traded under the ticker BAYRY. The drug is currently in Phase 1 clinical development for advanced non-small cell lung cancer.
BAY2927088 is in Phase 1 clinical development. A Phase 1 study has been completed that evaluated how the drug is taken up and handled by the body in healthy male participants. The drug is investigational and has not been approved by regulatory authorities.
BAY2927088 has one completed clinical trial, NCT06221475, which was a Phase 1 study in healthy male participants. The study enrolled 8 participants and was conducted in the Netherlands. It was an uncontrolled, open-label study that examined how the drug is absorbed and processed by the body.
Yes, BAY2927088 coated refers to the same drug as BAY2927088. The term 'coated' likely describes a specific formulation of the drug. The drug is being developed by Bayer AG for advanced non-small cell lung cancer and is currently in Phase 1 clinical development.